Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 7,040 Shares

Posted by Donald Scott on May 8th, 2026

Phibro Animal Health Corporation (NASDAQ:PAHC – Get Free Report) CEO Jack Bendheim sold 7,040 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $55.80, for a total transaction of $392,832.00. Following the sale, the chief executive officer owned 67,720 shares in the company, valued at $3,778,776. This represents a 9.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Bendheim also recently made the following trade(s):

On Thursday, May 7th, Jack Bendheim sold 4,528 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.49, for a total transaction of $219,562.72.
On Thursday, April 30th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.76, for a total transaction of $371,430.40.
On Tuesday, April 28th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $55.91, for a total transaction of $393,606.40.
On Wednesday, April 22nd, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.29, for a total transaction of $382,201.60.
On Thursday, April 16th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.64, for a total transaction of $384,665.60.
On Tuesday, April 14th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $59.08, for a total transaction of $415,923.20.
On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total transaction of $369,740.80.
On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.68, for a total transaction of $556,300.80.
On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.66, for a total transaction of $272,764.80.
On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.91, for a total transaction of $258,244.80.

Phibro Animal Health Stock Down 26.2%

PAHC stock opened at $43.16 on Friday. Phibro Animal Health Corporation has a 52-week low of $19.17 and a 52-week high of $60.08. The company’s 50 day simple moving average is $53.90 and its 200-day simple moving average is $46.51. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. The firm has a market capitalization of $1.75 billion, a P/E ratio of 18.52, a P/E/G ratio of 0.90 and a beta of 0.61.

Phibro Animal Health (NASDAQ:PAHC – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 38.70%. The business had revenue of $383.54 million for the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, equities research analysts anticipate that Phibro Animal Health Corporation will post 3.03 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 24th. Investors of record on Wednesday, June 3rd will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, June 3rd. This represents a $0.48 dividend on an annualized basis and a yield of 1.1%. Phibro Animal Health’s payout ratio is presently 20.60%.

Phibro Animal Health News Roundup

Here are the key news stories impacting Phibro Animal Health this week:

Positive Sentiment: Quarterly results beat expectations — Phibro reported $0.76 EPS vs. $0.72 consensus and revenue of $383.5M vs. $367.0M expected; net sales rose ~10% year-over-year and net income increased ~15%, highlighting continued top-line growth and margin improvement. Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
Positive Sentiment: Earnings/analyst coverage echoed the beat — multiple outlets and the company transcript highlight the upside vs. estimates, providing evidence the quarter was fundamentally stronger than consensus. Earnings Transcript and Summary
Neutral Sentiment: FY2026 guidance updated to $2.98–$3.10 EPS and revenue ~ $1.5B (range provided by company). The midpoint is close to analyst expectations (~$3.03), but the range left some uncertainty about the low end. Investors often react to the tone and range width as much as the midpoint. Updated Financial Guidance
Neutral Sentiment: Dividend declared — company announced a $0.12 quarterly dividend (record June 3, payable June 24), a small yield that supports income-focused holders but is unlikely to materially change valuation. (Company release)
Neutral Sentiment: Investor events and outreach — management will present at the Bank of America Healthcare Conference next week, offering an opportunity for real-time analyst Q&A and potential clarity on strategy and guidance execution. Conference Participation Announcement
Neutral Sentiment: Corporate sustainability initiative launched — new VERRATAIN™ sustainability platform and VAXA partnership may improve ESG positioning over time but is unlikely to drive near-term revenue. Sustainability Platform Announcement
Negative Sentiment: Revolving credit facility expansion raised investor concerns — coverage notes the company expanded its credit line, which some investors read as higher leverage risk or preparation for contingencies; combined with the company’s stated debt/equity profile, this likely increased selling pressure today. Investors Reacting to Revolving Credit Facility Expansion

Analyst Ratings Changes

PAHC has been the topic of a number of research analyst reports. Citigroup initiated coverage on shares of Phibro Animal Health in a research report on Wednesday, April 15th. They set a “neutral” rating and a $62.00 price objective on the stock. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. Finally, Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a research report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Phibro Animal Health has a consensus rating of “Hold” and an average target price of $42.40.

Get Our Latest Report on Phibro Animal Health

Institutional Trading of Phibro Animal Health

Large investors have recently added to or reduced their stakes in the business. KBC Group NV bought a new stake in Phibro Animal Health in the first quarter worth approximately $29,000. 1620 Investment Advisors Inc. grew its position in Phibro Animal Health by 77.4% in the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after acquiring an additional 295 shares in the last quarter. Farther Finance Advisors LLC grew its position in Phibro Animal Health by 113.2% in the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after acquiring an additional 386 shares in the last quarter. Hughes Financial Services LLC bought a new stake in Phibro Animal Health in the third quarter worth approximately $40,000. Finally, Rothschild Investment LLC grew its position in Phibro Animal Health by 2,500.0% in the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after acquiring an additional 1,000 shares in the last quarter. 99.34% of the stock is owned by institutional investors.

Phibro Animal Health Company Profile

(Get Free Report)

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.